PRSS16

Across TCGA pan-cancer cohorts, PRSS16 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated PRSS16 data layer compared with 3 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRSS16 RNA is associated with better overall survival. In most high-consensus cancer types, elevated PRSS16 expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

OV, SKCM, and READ are the cancer types where PRSS16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	All	0.773	0.625	<.001	90	view →
SKCM	DFS	Median	III,IV	0.711	0.365	<.001	59	view →
READ	DFS	Quartile	All	0.876	0.225	<.001	55	view →
MESO	OS	Quartile	All	0.689	0.385	.001	48	view →
BLCA	OS	Quartile	III,IV	0.807	0.587	.002	46	view →
KIRC	DFS	Median	II,III,IV	0.738	0.564	.006	33	view →
GBM	OS	Median	All	0.218	0.315	.022	21	view →
SCLC	OS	Median	II,III,IV	0.421	1.000	.002	19	view →
LIHC	OS	Tertile	All	0.610	0.729	.015	14	view →
CHOL	DFS	Median	III,IV	0.127	0.647	.006	12	view →
SARC	DFS	Median	All	0.676	0.550	.006	12	view →
ESCA	OS	Tertile	IV	0.238	0.738	.024	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

PRSS16–OV (OS)

Open the OV breakdown →